Cited by 995Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Comparative effectiveness of different treatment pathways for opioid use disorder.

Open access

Wakeman, Sarah E., Larochelle, Marc R., Ameli, Omid, Chaisson, Christine E., McPheeters, Jeffrey Thomas, Crown, William H., Azocar, Francisca, Sanghavi, Darshak M.·2020·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.20622PMC PMC11143463

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.20622

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citation
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

Flagged first, then by citations

Show all 39 references

3 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 995

Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data
Butelman, E. R., Huang, Y., McFarlane, A., Slattery, C., Goldstein, R. Z., Volkow, N. D., & Nelly Alia-klein, A. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112535 · Cited by 11
Potential improvement in spatial accessibility of methadone treatment with integration into other outpatient substance use disorder treatment programs, New York City, 2024
Bachhuber, M. A., Cunningham, C. O., & Jordan, A. E. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317967 · Cited by 10
How competing needs after incarceration lead to adverse health outcomes among people who use criminalized drugs
Paquette, C., Ehle, K., Roach, M., Danns, T., LeMasters, K. H., Craft, B., & Brinkley‐Rubinstein, L. (2025) · BMC Global and Public Health · doi:10.1186/s44263-025-00152-y · Cited by 10
Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
Kennedy‐Hendricks, A., Schilling, C. J., Busch, A. B., Stuart, E. A., Huskamp, H. A., Meiselbach, M. K., Barry, C. L., & Eisenberg, M. D. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07094-9 · Cited by 10
Attitudes Regarding Medications for Opioid Use Disorder Among Peer Recovery Coaches
Suzuki, J., Loguidice, F., & Martin, B. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001025 · Cited by 10
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants
Andraka‐Christou, B., Page, C., Schoebel, V., Buche, J., & Haffajee, R. L. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00321-6 · Cited by 10
Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings
Frost, M. C., Soyer, E. M., Achtmeyer, C. E., Hawkins, E. J., Glass, J. E., Hallgren, K. A., & Williams, E. C. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00382-1 · Cited by 9
It’s Time to Train Residents in Addiction Medicine
Sokolski, E., Buchheit, B. M., Desai, S. S., & Englander, H. L. (2023) · Journal of Graduate Medical Education · doi:10.4300/jgme-d-23-00317.1 · Cited by 10
Association between benzodiazepine coprescription and mortality in people on opioid replacement therapy: a population-based cohort study
Best, C. S., Matheson, C., Robertson, J. R., Ritchie, T., Cowden, F., Dumbrell, J., Duncan, C., Kessavalou, K., Woolston, C., & Schofield, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074668 · Cited by 10
Neither Ethical Nor Effective: The False Promise of Involuntary Commitment to Address the Overdose Crisis
Sinha, M. S., Messinger, J. C., & Beletsky, L. A. (2020) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110520979384 · Cited by 10
Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis
Rogal, S. S., Youk, A. O., Agbalajobi, O. M., Zhang, H., Gellad, W. F., Fine, M. J., Belperio, P. S., Morgan, T. R. M., Good, C. B., & Kraemer, K. L. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001228 · Cited by 10
Pharmacists should treat patients who have opioid use disorders, not police them
Chiarello, E. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.06.019 · Cited by 10
A national survey of state laws regarding medications for opioid use disorder in problem-solving courts
Andraka‐Christou, B., Randall-Kosich, O., Golan, M., Totaram, R., Saloner, B. K., Gordon, A. J., & Stein, B. D. (2022) · Health & Justice · doi:10.1186/s40352-022-00178-6 · Cited by 10
Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller, A., DiDomizio, E. E., Madden, L. M., Oliva, J. D., Altice, F. L., & Johnson, K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2084154 · Cited by 10
Optimally Choosing Medication Type for Patients With Opioid Use Disorder
Rudolph, K. E., Williams, N., Diaz, I. M., Luo, S. X., Rotrosen, J., & Nunes, E. V. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac217 · Cited by 10
A Health Crisis within a Health Crisis: Opioid Access in the Covid-19 Pandemic
Narayan, A. P., & Balkrishnan, R. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1900981 · Cited by 10
Using Data Science to Improve Outcomes for Persons with Opioid use Disorder
Hayes, C. J., Cucciare, M. A., Martin, B. C., Hudson, T. J., Bush, K., Lo‐Ciganic, W., Yu, H. Q., Charron, E. M., & Gordon, A. J. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2060446 · Cited by 10
Opioid Agonist Treatment Retention Among People Initiating Methadone and Buprenorphine Across Diverse Demographic and Geographic Subgroups in Ontario: A Population-based Retrospective Cohort Study
Elnagdi, A., McCormack, D., Bozinoff, N., Tadrous, M., Antoniou, T., Munro, C., Campbell, T. J., Paterson, J. M., Mamdani, M., Sproule, B. A., et al. (2023) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000192 · Cited by 9
Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022
Meyerson, B. E., Treiber, D., Brady, B. R., Newgass, K., Bondurant, K., Bentele, K. G., Samorano, S., Arredondo, C., & Stavros, N. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209306 · Cited by 9
Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis
Wurcel, A. G., Suzuki, J., Schranz, A. J., Eaton, E., Cortes-Penfield, N. W., & Baddour, L. M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.034 · Cited by 9
Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood
Hu, J., Kulkarni, N., Maliha, P., & Grossberg, G. T. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s375653 · Cited by 9
Patient experiences of buprenorphine dispensing from a mobile medical unit
Messmer, S., Elmes, A. T., Infante, A. F., Patterson, A., Smith, M., Murphy, A. L., Jimenez, A. D., Mayer, S., Watson, D. P., Whitfield, K., et al. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00484-4 · Cited by 9
Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment: A Systematic Review of the Evidence
Matheson, C., Vucic, C., Dumbrell, J., Robertson, R., Ritchie, T., Duncan, C., Kessavalou, K., Woolston, C., & Schofield, J. (2024) · Pharmacy · doi:10.3390/pharmacy12050152 · Cited by 10
Use of Medications for Opioid Use Disorder in Older Adults
Kuo, Y., Westra, J. R., Harvey, E. P., & Raji, M. A. (2025) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2025.01.019 · Cited by 9
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol
Freet, C. S., Shuler, K., Kawasaki, S. S., Weintraub, E., Greenblatt, A. D., Kladney, M., Nunes, E. V., Foster, K. L., Kong, L., Raja-Khan, N. T., et al. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00618-2 · Cited by 10
Whose opinion matters about medications for opioid use disorder? A cross-sectional survey of social norms among court staff
Andraka‐Christou, B., & Atkins, D. N. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1846666 · Cited by 9
Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study
Welsh, J. W., Mataczynski, M. J., Passetti, L. L., Hunter, B. D., & Godley, M. D. (2022) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2022.2043335 · Cited by 9
Caracterização do cuidado de enfermagem numa equipa de tratamento para os comportamentos aditivos e dependências
de Lisboa, E. S. D. E., Seabra, P., Simões, A., Equipa Técnica Especializada do Barreiro, C. P. D. S., Sequeira, A., Equipa Técnica Especializada do Barreiro, C. P. D. S., Amaral, P., Equipa Técnica Especializada do Barreiro, C. P. D. S., Filipe, F., Equipa Técnica Especializada do Barreiro, C. P. D. S., et al. (2021) · Revista Portuguesa de Enfermagem de Saúde Mental · doi:10.19131/rpesm.311 · Cited by 9
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder
Gopaldas, M., Wenzel, K. R., Campbell, A. N. C., Jalali, A., Fishman, M. J., Rotrosen, J., Nunes, E. V., & Murphy, S. M. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220549 · Cited by 9
Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder
Eglovitch, M., Parlier‐Ahmad, A. B., Legge, C., Chithranjan, S., Kolli, S., Violante, S., Dzierzewski, J. M., Huhn, A. S., Wilkerson, A. K., & Martin, C. E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1244156 · Cited by 9
Trends in Adult ADHD Diagnosis and Treatment in Patients with Opioid Use Disorder in the United States
Park, T., Baul, T. D., Morgan, J. R., Wilens, T., & Yule, A. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220400 · Cited by 8
Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders
Liu, P., Korthuis, P. T., & Buchheit, B. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033924 · Cited by 9
A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements
Andraka‐Christou, B., Golan, O. K., Williams, M., Buksbaum, S., Gordon, A. J., & Stein, B. D. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342231223721 · Cited by 9
Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice
Deyo-Svendsen, M. E., Svendsen, M. C., Walker, J. E., Hodges, A., Oldfather, R. Z., & Mansukhani, M. P. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720931720 · Cited by 9
How a Medication for Opioid Use Disorder Curriculum Translates into Experiences and Internal Medicine Residents’ Understanding of Patients with Opioid Use Disorder
Robles, M., Mortazavi, L., Vannerson, J., & Matthias, M. S. (2021) · Teaching and Learning in Medicine · doi:10.1080/10401334.2021.1897597 · Cited by 9
CommunityStat: A Public Health Intervention to Reduce Opioid Overdose Deaths in Burlington, Vermont, 2017–2020
del Pozo, B. (2021) · Contemporary Drug Problems · doi:10.1177/00914509211052107 · Cited by 9
Social determinants of health and emergency department utilization among adults receiving buprenorphine for opioid use disorder
Radic, M., Parlier‐Ahmad, A. B., Wills, B. K., & Martin, C. E. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100062 · Cited by 9
Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach
Jones, K. F., Jacob, M. O., Spetz, J., Hailer, L., & Tierney, M. (2023) · Journal of Nursing Scholarship · doi:10.1111/jnu.12871 · Cited by 9
Generational trends in US opioid-overdose deaths
Hall, W., Degenhardt, L. J., & Hickman, M. (2020) · Nature Medicine · doi:10.1038/s41591-020-0875-7 · Cited by 9
Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review
Chan, B. L., Gean, E. G., Arkhipova-Jenkins, I., Gilbert, J., Hilgart, J., Fiordalisi, C. V., Hubbard, K., Brandt, I., Stoeger, E., Paynter, R. A., et al. (2020) · doi:10.23970/ahrqepcrapidmat · Cited by 9
Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review
Bailey, A., DaCunha, A., Napoleon, S. C., Kang, A. W. C., Kemo, M., & Martin, R. A. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209431 · Cited by 8
Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments
Kumar, P., Kaliamurthy, S., & Thomas, J. (2024) · PEDIATRICS · doi:10.1542/peds.2024-066226 · Cited by 8
Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder
Biondi, B. E., Munroe, S., Lavarin, C., Curtis, M. R., Buzzee, B., Lodi, S., & Epstein, R. L. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae426 · Cited by 8
Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study
Hasan, M., Meador, K. J., Brothers, T. N., Wang, S., Lewkowitz, A. K., Ward, K. E., Slaughter, J. L., Zhang, Y., & Wen, X. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4616 · Cited by 8
A Single‐Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Monthly Extended-Release Buprenorphine at Alternative Injection Locations in Adult Participants with Opioid Use Disorder
Laffont, C. M., Lapeyra, O., Mangal, D., & Dobbins, R. L. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01406-7 · Cited by 8
Emerging medications and pharmacological treatment approaches for substance use disorders
Raymond, J. S., Athanasopoulos, A. G., Badolato, C. J., Doolan, T. M., Scicluna, R. L., Everett, N. A., Bowen, M. T., & James, M. H. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173952 · Cited by 9
The Donovan Memorial Lecture: ‘Fentanyl-Plus’: A New Era of Fentanyl Polydrug Combinations in the North American Overdose Crisis
Ciccarone, D. (2025) · Journal of Medical Toxicology · doi:10.1007/s13181-025-01104-6 · Cited by 10
Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada
Young, S., Hayashi, K., Grant, C. J., Milloy, M., DeBeck, K., Wood, E., & Fairbairn, N. S. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109006 · Cited by 8
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
Bazazi, A. R., Culbert, G. J., Wegman, M. P., Heimer, R., Kamarulzaman, A., & Altice, F. L. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07804-6 · Cited by 8
Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study
Faude, S., Delgado, M. K., Perrone, J., McFadden, R. B., Xiong, R. A., O'Donnell, N., Wood, C., Solomon, G., & Lowenstein, M. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.01.009 · Cited by 8
Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis
Ledlie, S., Tadrous, M., Bayoumi, A. M., McCormack, D., Cheng, C., Besharah, J., Munro, C., & Gomes, T. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104392 · Cited by 8
Predictability of buprenorphine‐naloxone treatment retention: A multi‐site analysis combining electronic health records and machine learning
Haredasht, F. N., Fouladvand, S., Tate, S., Chan, M. M., Yeow, J., Griffiths, K., López, I., Bertz, J. W., Miner, A. S., Hernandez‐Boussard, T., et al. (2024) · Addiction · doi:10.1111/add.16587 · Cited by 8
Affordable transportation access to treatment for opioid use disorder
Ngo, N. S., & Anand, K. V. (2024) · Transport Policy · doi:10.1016/j.tranpol.2024.08.001 · Cited by 8
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
Hooker, S. A., Starkey, C., Bart, G. B., Rossom, R. C., Kane, S. M., & Olson, A. W. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02609-9 · Cited by 8
Risk of Oral Health Problems in Adults With Opioid Use Disorder Treated With Transmucosal Buprenorphine
Tuan, W., Clebak, K. T., Jawadi, E., Snyder, J., & Zgierska, A. E. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001453 · Cited by 8
Substance Addiction Consequences: Outpatients Severity Indicators in a Medication-Based Program
Seabra, P., Sequeira, A., Filipe, F., Amaral, P. E., Simões, A., & Sequeira, R. (2021) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-021-00485-3 · Cited by 7
Racial equity in linkage to inpatient opioid use disorder treatment in patients that received emergency care
Faiz, J., Bernstein, E., Dugas, J. N., Schechter‐Perkins, E. M., Nentwich, L. M., Nelson, K. P., Manchanda, E. C. C., Young, L., & Pare, J. R. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.037 · Cited by 8
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials
Shulman, M., Hu, M., Sullivan, M. A., Akerman, S. C., Fratantonio, J. L., Barbieri, V. A., Nunes, E. V., & Bisaga, A. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109343 · Cited by 8
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders
Raji, M. A., Priyadarshni, S., Yu, X., Digbeu, B. D. E., & Kuo, Y. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.032 · Cited by 8
A content review of buprenorphine training programs for pharmacists
Davis, S., Dryer, R., Zule, W. A., Ostrach, B. M. M., & Carpenter, D. M. (2022) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2022.100154 · Cited by 8
The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State
Banta‐Green, C. J., Owens, M. D., Williams, J. R., Sears, J. M., Floyd, A. S., Williams‐Gilbert, W., & Kingston, S. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00315-4 · Cited by 8
Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study
Wang, S., Meador, K. J., Pawasauskas, J. E., Lewkowitz, A. K., Ward, K. E., Brothers, T. N., Hartzema, A. G., Quilliam, B. J., & Wen, X. (2023) · Drug Safety · doi:10.1007/s40264-022-01267-z · Cited by 8
What can we learn from COVID-19 to improve opioid treatment? Expert providers respond
Harris, L. M., Marsh, J. C., Khachikian, T., Serret, V., Kong, Y., & Guerrero, E. G. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209157 · Cited by 8
In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder
Calcaterra, S. L., Saunders, S., Grimm, E., Maki-Gianani, E., Keniston, A., Wold, A., & Bonaguidi, A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08411-0 · Cited by 8
Biotechnologies and the future of opioid addiction treatments
Wolfe, D., & Saucier, R. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.103041 · Cited by 8
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
Jain, P., McKinnell, K., Marino, R., Vunnava, P., Liles-Burden, M. A., Desai, A., Wenten, M., Fratantonio, J. L., Akerman, S. C., Sullivan, M. A., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-01020-4 · Cited by 8
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
Anderson, K. E., Saloner, B. K., Eckstein, J., Chaisson, C. E., Scholle, S. H., Niles, L. L., Dy, S. M., & Alexander, G. C. (2021) · Medical Care · doi:10.1097/mlr.0000000000001530 · Cited by 8
Self-citation
Commentary on Karnik et al.: Harmonization now—the need for consistent, validated measures to identify opioid use disorder in observational data
Morgan, J. R., & Larochelle, M. R. (2022) · Addiction · doi:10.1111/add.15977 · Cited by 8
Self-citation
Misclassification of overdose events in the X:BOT study
Dasgupta, N., Ajazi, E., Schwartz, T. A., & Marshall, S. W. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00113-7 · Cited by 8
Recommendations for managing adults with chronic non‐cancer pain in primary care: A systematic clinical guideline review
Mazurenko, O., O’Brien, E., Beug, A., Smith, S. M., & McCarthy, C. (2024) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.14118 · Cited by 7
Unrelieved pain and risk of opioid use disorder or overdose in older adults prescribed opioids
Wei, Y. J., Schmidt, S. O., Fillingim, R. B., Brock, G. N., Schmidt, S., & Winterstein, A. G. (2025) · Pain · doi:10.1097/j.pain.0000000000003589 · Cited by 7
Medications for Opioid Use Disorder: Patients’ Experience, Knowledge, and Preferences in the Era of Illicitly Manufactured Fentanyl
Casey, S. K., McGovern, S., Regan, S., & Wakeman, S. E. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251326339 · Cited by 7
Self-citation
Quantifying Barriers to Medications for Opioid Use Disorder in Skilled Nursing Facilities in a Southwestern Metropolitan Area
Gutfrucht, B., & Barrett, E. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.037 · Cited by 7
Impact of Medicaid Expansion on Inclusion of Medications for Opioid Use Disorder in Homeless Adults’ Treatment Plans
Swartz, N., Odayappan, S., Chatterjee, A., & Cutler, D. (2022) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209059 · Cited by 7
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership
Burke, K., Krawczyk, N., Li, Y., Byrne, L., Desai, I. K., Bandara, S., & Feder, K. A. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209351 · Cited by 7
Challenges and recommendations for overdose prevention and harm reduction in an era of fentanyl and xylazine: Perspectives of women with opioid use disorder and professionals.
Harrison, E., Brant, K., Strong-Jones, S., Skogseth, E. M., Latkin, C. A., & Jones, A. A. (2024) · Psychology of Addictive Behaviors · doi:10.1037/adb0001021 · Cited by 7
Serum cytokines and inflammatory proteins in individuals with heroin use disorder: potential mechanistically based biomarkers for diagnosis
Butelman, E. R., Huang, Y., Cathomas, F., Gaudreault, P., Roussos, P., Russo, S. J., Goldstein, R. Z., & Alia‐Klein, N. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03119-z · Cited by 10
Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research
Lowry, N., Najia, C., Kelleher, M., Mitcheson, L., & Marsden, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088617 · Cited by 8
Differential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens
Gildawie, K. R., Budge, K. E., Vassoler, F. M., Yen, E., & Byrnes, E. M. (2024) · Developmental Psychobiology · doi:10.1002/dev.70015 · Cited by 7
Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale
Tomaszewski, C., Quenzer, F. C., Corbett, B. M., Lafree, A., Lasoff, D. R., Romo, J., & Mukau, L. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12462 · Cited by 7
Time to address addiction treatment inequality in hospital settings
Nielsen, S., & Lubman, D. I. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00260-7 · Cited by 7
Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers
Sung, M., Black, A. C., Blevins, D., Henry, B. F., Cates‐Wessel, K., Dawes, M. A., Drexler, K. P. G., Hagle, H., Molfenter, T. D., LEVIN, F. R., et al. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000948 · Cited by 7
Perceptions of E-cigarettes among adults in treatment for opioid use disorder
Streck, J. M., Regan, S., Kalkhoran, S. M., Kalagher, K. M., Bearnot, B. I., Gupta, P. S., Wakeman, S. E., & Rigotti, N. A. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100023 · Cited by 7
Self-citation
Perception of Resource Allocations to Address the Opioid Epidemic
Strickland, J. C., Victor, G. A., & Ray, B. R. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000971 · Cited by 7
Reducing stigma toward medication for opioid use disorder through social work education, research, and practice
Pasman, E. (2021) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2022.2016339 · Cited by 7
Substance use treatment services for older adults in five states in the Southern United States: a state-by-state comparison of available treatment services
Mumba, M. N., Jaiswal, J., Bui, C., Evans, T., Mainzinger, L., Davis, L. L., & Mugoya, G. C. T. (2022) · Aging & Mental Health · doi:10.1080/13607863.2022.2098911 · Cited by 8
Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada
Cui, Z., Bach, P., Ti, L., Hayashi, K., Morgan, J., Milloy, M., & Kerr, T. H. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103879 · Cited by 7
Disparities in opioid use disorder–related hospital use among postpartum Virginia Medicaid members
Martin, C. E., Britton, E., Shadowen, H. M., Bachireddy, C., Harrell, A., Zhao, X., & Cunningham, P. J. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2022.208935 · Cited by 7
“Knowing or not knowing”: Living as harm reductionists in Twelve Step recovery
Gannon, K., & Pasman, E. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.208954 · Cited by 7
“I’m Clean and Sober, But Not Necessarily Free”: Perceptions of Buprenorphine Among Patients in Long-Term Treatment
Wyse, J. J. B., Lovejoy, T. I., Gordon, A. J., Mackey, K., Herreid-O’Neill, A., & Morasco, B. J. (2023) · Substance Abuse · doi:10.1177/08897077231165625 · Cited by 7
Predictors of Linkage to an Opioid Treatment Program and Methadone Treatment Retention following Hospital Discharge in a Safety-Net Setting
Tierney, H. R., Takimoto, S. W., Azari, S., Steiger, S., & Martín, M. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2212070 · Cited by 7
Civil commitment perspectives and experiences among friends and family of people who use illicit opioids in Massachusetts, USA
Slocum, S., Paquette, C. E., Walley, A. Y., & Pollini, R. A. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104074 · Cited by 7
Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial
Lee, J. D., Nunes, E. V., Novo, P., May, J. M., Matthews, A. G., Veldhuisen, P. C. V., Lindblad, R., Liu, D., & Rotrosen, J. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000930 · Cited by 7
Pharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review
Ellerbroek, H., Kalkman, G. A., Kramers, C., Schellekens, A., & van den Bemt, B. J. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247770 · Cited by 6
Comparing and Integrating the 12-Step Recovery Model and Classical Medical Model: Toward a Holistic Framework for Addiction Treatment
Ungar-Sargon, J. Y. (2025) · Addiction Research · doi:10.33425/2639-8451.1051 · Cited by 6
Trends in U.S. Adolescent and Young Adult Overdose Fatalities, 1999-2023
Chen, Y., Seiters, H., Wang, Z., & Bell, L. A. (2025) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2025.06.023 · Cited by 6
Cannabis use and opioid relapse: An exploratory survival analysis of prospectively collected data
Naji, L., Rosic, T., Sanger, N., Dennis, B. B., Hillmer, A., Hudson, J., Worster, A., Paul, J., Marsh, D. C., Thabane, L., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1046649 · Cited by 6
Predictors of Retention and Drug Use Among Patients With Opioid Use Disorder Transferred to a Specialty “Second Chance” Methadone Program
Moses, T. E. H., Rhodes, G. L., Tavakoli, E., CHRISTENSEN, C. W., Amirsadri, A., & Greenwald, M. K. (2022) · Substance Abuse Research and Treatment · doi:10.1177/11782218221138335 · Cited by 6
Patient and Provider Perspectives on Processes of Engagement in Outpatient Treatment for Opioid Use Disorder: A Scoping Review
Austin, E. J., OʼBrien, Q., Ruiz, M. S., Ratzliff, A., Williams, E. C., & Koch, U. (2023) · Community Mental Health Journal · doi:10.1007/s10597-023-01175-1 · Cited by 6
The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder
Banks, M. L., & Sprague, J. E. (2024) · Addiction Biology · doi:10.1111/adb.13369 · Cited by 6

Authors: Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
Affiliations: Harvard University (US)
Boston University (US)
Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
Optum (United States) (US)
Department of Research, OptumLabs, Cambridge, Massachusetts
Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
UnitedHealth Group (United States) (US)
Corresponding author: Wakeman, Sarah E.
ORCID: Wakeman, Sarah E.
Larochelle, Marc R.
Ameli, Omid
Chaisson, Christine E.
Crown, William H.
Azocar, Francisca
Sanghavi, Darshak M.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2020-02-05
Volume: 3
Issue: 2
Pages: e1920622
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.20622
PMC: PMC11143463
OpenAlex: W3005454586
Cited by: 995
References: 39
Citations by year: 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
FWCI: 92.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Network Open (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
School of Medicine, Boston University (1UL1TR001430)
Laura and John Arnold Foundation
Office of National Drug Control Policy (G1799ONDCP06B)
Hamilton Health Sciences Foundation
National Institutes of Health (UL1TR001430)
Centers for Disease Control and Prevention (U01CE002780)
U.S. Food and Drug Administration (HHSF223200910006I)
Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative effectiveness of different treatment pathways for opioid use disorder.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks